These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26617215)

  • 21. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates.
    Pandey SC; Davis JM; Pandey GN
    J Psychiatry Neurosci; 1995 May; 20(3):215-25. PubMed ID: 7786883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
    Zaniewska M; McCreary AC; Przegaliński E; Filip M
    Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration.
    Vicente MA; Zangrossi H
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):389-400. PubMed ID: 21733232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
    Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational approaches to the design of novel 5-HT6 R ligands.
    Ivanenkov YA; Majouga AG; Veselov MS; Chufarova NV; Baranovsky SS; Filkov GI
    Rev Neurosci; 2014; 25(3):451-67. PubMed ID: 24867282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.
    Leopoldo M; Lacivita E; Berardi F; Perrone R; Hedlund PB
    Pharmacol Ther; 2011 Feb; 129(2):120-48. PubMed ID: 20923682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
    Seimandi M; Bockaert J; Marin P
    Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of RNA editing of the serotonin 2C receptor (5-HT(₂C)R) ex vivo.
    Lanfranco MF; Anastasio NC; Seitz PK; Cunningham KA
    Methods Enzymol; 2010; 485():311-28. PubMed ID: 21050925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2.
    Werry TD; Gregory KJ; Sexton PM; Christopoulos A
    J Neurochem; 2005 Jun; 93(6):1603-15. PubMed ID: 15935077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
    Alex KD; Pehek EA
    Pharmacol Ther; 2007 Feb; 113(2):296-320. PubMed ID: 17049611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs.
    Martin CB; Hamon M; Lanfumey L; Mongeau R
    Neurosci Biobehav Rev; 2014 May; 42():208-23. PubMed ID: 24631644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
    Ivachtchenko AV; Ivanenkov YA; Skorenko AV
    Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin receptor ligands and the treatment of obesity.
    Vickers SP; Dourish CT
    Curr Opin Investig Drugs; 2004 Apr; 5(4):377-88. PubMed ID: 15134278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation following nicotine withdrawal in rats.
    Zaniewska M; Alenina N; Wydra K; Fröhler S; Kuśmider M; McCreary AC; Chen W; Bader M; Filip M
    J Neurochem; 2015 Aug; 134(4):704-16. PubMed ID: 26031442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.